Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes.
暂无分享,去创建一个
L. E. Lovblom | A. Orszag | B. Perkins | J. Lovshin | M. Brent | V. Bril | D. Cherney | P. Bjornstad | Y. Lytvyn | V. Lai | A. Weisman | D. Scarr | H. Keenan | Geneviève Boulet | Josephine Tse | Leslie Cham | Narinder Paul | Mohammed A. Farooqi | L. Lovblom
[1] C. Kanaka-Gantenbein,et al. Diabetic nephropathy in type 1 diabetes. , 2018, Minerva medica.
[2] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[3] M. Phillip,et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.
[4] P. Lapuerta,et al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes , 2017, The New England journal of medicine.
[5] J. Lovshin,et al. Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? , 2017, Current opinion in nephrology and hypertension.
[6] D. Dunger,et al. The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. , 2017, American journal of physiology. Renal physiology.
[7] S. Anderson,et al. A Contemporary Estimate of Total Mortality and Cardiovascular Disease Risk in Young Adults With Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study , 2016, Diabetes Care.
[8] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[9] D. Maahs,et al. The Gomez' equations and renal hemodynamic function in kidney disease research. , 2016, American journal of physiology. Renal physiology.
[10] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[11] BouletGeneviève,et al. Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes , 2016 .
[12] J. Shaw,et al. Age-Specific Trends From 2000–2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People , 2016, Diabetes Care.
[13] Elise M. Halpern,et al. Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes , 2016, Diabetes Care.
[14] A. Tsapas,et al. Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .
[15] Connie M. Rhee,et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] Alan B Leichtman,et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] U. Broedl,et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. , 2014, Kidney international.
[18] U. Broedl,et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration , 2014, Diabetologia.
[19] D. Maahs,et al. Early diabetic nephropathy in type 1 diabetes: new insights , 2014, Current opinion in endocrinology, diabetes, and obesity.
[20] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[21] P. Peduzzi,et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.
[22] J. Scholey,et al. The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes , 2013, Diabetologia.
[23] A. Galecki,et al. Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study , 2013, Current Diabetes Reports.
[24] P. McFarlane,et al. Chronic kidney disease in diabetes. , 2013, Canadian journal of diabetes.
[25] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.
[26] Merlin C. Thomas,et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications , 2012, Journal of hypertension.
[27] Jiang He,et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.
[28] J. Scholey,et al. The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] Xiaoyan Wang,et al. SDF‐1α/CXCR4 axis is involved in glucose‐potentiated proliferation and chemotaxis in rat vascular smooth muscle cells , 2010, International journal of experimental pathology.
[30] J. Scholey,et al. The Acute Effect of Clamped Hyperglycemia on the Urinary Excretion of Inflammatory Cytokines/Chemokines in Uncomplicated Type 1 Diabetes , 2010, Diabetes Care.
[31] R. G. Miller,et al. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2010, Diabetologia.
[32] E. Abdel-Rahman,et al. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[33] B. Zinman,et al. Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[34] B. Zinman,et al. Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes , 2009, Diabetes Care.
[35] Edward G Lakatta,et al. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. , 2009, The Medical clinics of North America.
[36] Merlin C. Thomas,et al. The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.
[37] J. Velez. The importance of the intrarenal renin–angiotensin system , 2009, Nature Clinical Practice Nephrology.
[38] B. Zinman,et al. Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study , 2009, Diabetes Care.
[39] J. Scholey,et al. Insights into the regulation of renal hemodynamic function in diabetic mellitus. , 2008, Current diabetes reviews.
[40] G. Tangelder,et al. Preglomerular and postglomerular basal diameter changes and reactivity to angiotensin II in obese rats , 2008, Diabetes, obesity & metabolism.
[41] S. Yusuf,et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.
[42] B. Williams,et al. Angiotensin II–Mediated Oxidative DNA Damage Accelerates Cellular Senescence in Cultured Human Vascular Smooth Muscle Cells via Telomere-Dependent and Independent Pathways , 2008, Circulation research.
[43] Jennifer K. Sun,et al. Clinical Factors Associated With Resistance to Microvascular Complications in Diabetic Patients of Extreme Disease Duration , 2007, Diabetes Care.
[44] D. Gordin,et al. Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes , 2007, Diabetologia.
[45] A. Vinik,et al. Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.
[46] J. Scholey,et al. Gender differences in the renal response to renin-angiotensin system blockade. , 2006, Journal of the American Society of Nephrology : JASN.
[47] J. Scholey,et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. , 2006, Journal of the American Society of Nephrology : JASN.
[48] E. Sochett,et al. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. , 2005, Kidney international.
[49] J. Scholey,et al. Endothelial nitric oxide synthase gene/gender interactions and the renal hemodynamic response to angiotensin II. , 2005, Journal of the American Society of Nephrology : JASN.
[50] A. Reunanen,et al. Altered Age-Related Blood Pressure Pattern in Type 1 Diabetes , 2004, Circulation.
[51] R. Carey,et al. The intrarenal renin–angiotensin system and diabetic nephropathy , 2003, Trends in Endocrinology & Metabolism.
[52] A. Sved,et al. Acute sympathoexcitatory action of angiotensin II in conscious baroreceptor-denervated rats. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.
[53] G. Crepaldi,et al. Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes. , 2002, European journal of endocrinology.
[54] Michael E. Miller,et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. , 2002, Diabetes.
[55] J. Floras,et al. Variation in the renin angiotensin system throughout the normal menstrual cycle. , 2002, Journal of the American Society of Nephrology : JASN.
[56] M. Emoto,et al. Diabetes mellitus Worsens Intrarenal Hemodynamic Abnormalities in Nondialyzed Patients with Chronic Renal Failure , 2000, Nephron.
[57] N. Hollenberg,et al. The paradox of the low-renin state in diabetic nephropathy. , 1999, Journal of the American Society of Nephrology : JASN.
[58] J. Miller,et al. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. , 1999, Journal of the American Society of Nephrology : JASN.
[59] F. Logerfo,et al. Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. , 1998, Journal of vascular surgery.
[60] B. Zinman,et al. Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. , 1996, Clinical science.
[61] A. Krolewski,et al. Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of the Angiotensin I–Converting Enzyme Gene , 1994, Diabetes.
[62] J. Flier,et al. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. , 1987, The New England journal of medicine.
[63] B. Brenner,et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.
[64] D. Gómez,et al. Evaluation of renal resistances, with special reference to changes in essential hypertension. , 1951, The Journal of clinical investigation.
[65] N. Chavez-Tapia,et al. Diabetic cardiovascular autonomic neuropathy : A review , 2017 .
[66] H. Parving,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[67] R. Beck. Glycemic control and excess mortality in type 1 diabetes. , 2015, The New England journal of medicine.
[68] D. Maahs,et al. Update on Estimation of Kidney Function in Diabetic Kidney Disease , 2015 .
[69] Lawrence A Leiter,et al. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee , 2013 .
[70] E. Lewis,et al. Pyridorin in type 2 diabetic nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.
[71] B. Zinman,et al. Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: a pilot study. , 2012, Canadian journal of physiology and pharmacology.
[72] J. Tamsma,et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. , 2009, The New England journal of medicine.
[73] N. Hollenberg,et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. , 2003, Kidney international.
[74] D. Cattran,et al. Impact of gender on the renal response to angiotensin II. , 1999, Kidney international.
[75] J. Wetzels,et al. The changing natural history of nephropathy in type I diabetes. , 1986, The American journal of medicine.